Michael W. Draper - Concepedia

Author

Michael W. Draper

Also Known As

M W Draper, M. W. DRAPER, M. W. Draper, M.W Draper, M.W. DRAPER, M.W. Draper, MICHAEL W. DRAPER, Michael W Draper, Michael W. Draper

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)University of California, San Francisco Indiana University – Purdue University Indianapolis

About

Michael W. Draper is an author at Eli Lilly (United States) specializing in medicine, endocrinology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	486
2	Biochemistry	2	2	59
3	Health Sciences	1	1	21
4	Natural Sciences	1	1	18
5	Public Health	1	1	53

Michael W. Draper

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women Michael W. Draper, David E. Flowers, William J. Huster, Journal of Bone and Mineral Research	1996	355
Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women C. Conrad Johnston, Nina H. Bjarnason, Fredric J. Cohen, Archives of Internal Medicine	2000	211
Effects of raloxifene hydrochloride on the endometrium of postmenopausal women Susan M. Boss, William J. Huster, Julie A. Neild, American Journal of Obstetrics and Gynecology MedicinePharmacologyGynecologyMenopauseMenstrual Cycle	1997	146
Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF‐I concentrations Lester Cohn, Axel G. Feller, Michael W. Draper, Clinical Endocrinology	1993	139
Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years E. Jolly, Nina H. Bjarnason, Patrick Neven, Menopause The Journal of The North American Menopause Society	2003	107
Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene P. J. Meunier, E. Vignot, Patrick Garnero, Osteoporosis International Bone DiseaseBone HealthOsteopathyGynecologyMenopause	1999	96
Raloxifene and Estrogen: Comparative Bone-Remodeling Kinetics<sup>1</sup> Robert P. Heaney, Michael W. Draper The Journal of Clinical Endocrinology & Metabolism	1997	88
Raloxifene is a Tissue‐Selective Agonist/Antagonist That Functions through the Estrogen Receptor Robin Fuchs‐Young, A. L. GLASEBROOK, Lorri L. Short, Annals of the New York Academy of Sciences Molecular PharmacologyMedicineHormonal ReceptorEstrogen ReceptorMechanism Of Action	1995	87
A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women Ian R. Reid, Richard Eastell, Ignac Fogelman, Archives of Internal Medicine	2004	80
Raloxifene Treatment Is Associated With Increased Serum Estradiol and Decreased Bone Remodeling in Healthy Middle-Aged Men With Low Sex Hormone Levels Brigitte Uebelhart, François R. Herrmann, Imre Pávó, Journal of Bone and Mineral Research	2004	53

Page 1